Medpace Holdings, Inc. Common Stock

MEDP trades at a surprisingly lofty 25.9x earnings despite its RSI of 36.8 indicating oversold momentum conditions—an unusual disconnect suggesting either elevated growth expectations or complacency about valuation risk. The $14.1B market cap reflects strong institutional confidence in the CRO sector, yet with short interest at just 5.85%, there's minimal squeeze potential to catalyze a reversal. The stock sits well below its 52-week high, creating a modest technical setup where mean reversion could offer relief, though the premium multiple leaves limited room for multiple compression without a material earnings stumble.